ISRCTN71212234 https://doi.org/10.1186/ISRCTN71212234

# Chemotherapy with MOPP versus hybrid MOPP /EVAP in advanced Hodgkin's disease

| | | |
|---|---|---|
| **Submission date**<br>01/07/2001 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[_] Results<br>[_] Individual participant data<br>[_] Record updated in last year |
| **Registration date**<br>01/07/2001 | **Overall study status**<br>Completed | |
| **Last Edited**<br>21/01/2019 | **Condition category**<br>Cancer | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr - -

**Contact details**
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**
H14

## Study information

## Scientific Title
Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease

## Study objectives
Not provided at time of registration

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
Not provided at time of registration

## Study design
Randomised controlled trial

## Primary study design
Interventional

## Secondary study design
Randomised controlled trial

## Study setting(s)
Hospital

## Study type(s)
Treatment

## Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied
Lymphoma (Hodgkin's)

## Interventions
Patients are randomised to one of two chemotherapy regimens:
1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated every 4 weeks for a minimum of four courses.
2. MOPP/EVAP Regimen: Multi-drug chemotherapy with MOPP alternating every 2 weeks with etoposide, vinblastine, adriamycin and prednisolone (EVAP) for a minimum of eight courses of chemotherapy (ie four courses each of MOPP and EVAP).

## Intervention Type
Drug

## Phase
Not Applicable

## Primary outcome measure
Not provided at time of registration

### Secondary outcome measures
Not provided at time of registration

### Overall study start date
01/01/1989

### Completion date
01/10/1993

## Eligibility

### Key inclusion criteria
1. Hodgkin's lymphoma stage IIB, III or IV
2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV)
3. Local hisopathological review of diagnosis
4. No medical contraindications to treatment protocols

### Participant type(s)
Patient

### Age group
Not Specified

### Sex
Not Specified

### Target number of participants
Not provided at time of registration

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
01/01/1989

### Date of final enrolment
01/10/1993

## Locations

### Countries of recruitment
England

United Kingdom

### Study participating centre

**MRC Clinical Trials Unit**
London
United Kingdom
NW1 2DA

# Sponsor information

**Organisation**
Cancer Research UK (CRUK) (UK)

**Sponsor details**
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

**Sponsor type**
Charity

**Website**
http://www.cancer.org.uk

**ROR**
https://ror.org/054225q67

# Funder(s)

**Funder type**
Charity

**Funder Name**
Cancer Research UK

**Alternative Name(s)**
CR_UK, Cancer Research UK - London, CRUK

**Funding Body Type**
Private sector organisation

**Funding Body Subtype**
Other non-profit organizations

**Location**
United Kingdom

# Results and Publications

**Publication and dissemination plan**
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration